MIFCOR

MIFCOR was an early-stage private biotechnology company developing therapies to protect tissues from ischemic injury, particularly in settings such as heart attack and acute kidney injury. The company’s lead concept centered on MIF-2 and related MIF-pathway modulators intended to activate endogenous pro-survival mechanisms and reduce cell death after reduced blood flow. Public company-profile sources describe MIFCOR as founded in 2014 in New Haven, Connecticut, with technology licensed from Yale University and modest seed/non-dilutive support. Although multiple business databases still describe the company as active, Connecticut state records indicate the legal entity status is withdrawn, so it appears inactive as a corporate entity. Overall, MIFCOR looks best characterized as a Yale-linked preclinical ischemia therapeutics startup built around MIF-family biology.